Cargando…

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting. However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated detection of the B cell, tumor-specific antigen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farren, T W, Giustiniani, J, Fanous, M, Liu, F, Macey, M G, Wright, F, Prentice, A, Nathwani, A, Agrawal, S G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314455/ https://www.ncbi.nlm.nih.gov/pubmed/25615279 http://dx.doi.org/10.1038/bcj.2014.92

Ejemplares similares

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay
por: Farren, Timothy W., et al.
Publicado: (2020)

Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia
por: Bozorgmehr, Najmeh, et al.
Publicado: (2021)

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
por: Gauci, Marie-Léa, et al.
Publicado: (2022)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms
por: El- Neanaey, Wafaa Ahmed, et al.
Publicado: (2020)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Publicado: (2021)

Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia
por: Assumpção, Juliana Godoy, et al.
Publicado: (2013)

Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting
por: Ringelstein-Harlev, Shimrit, et al.
Publicado: (2014)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

Increased autocrine interleukin‐6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia
por: Wang, Hua‐Qing, et al.
Publicado: (2019)

CD160 isoforms and regulation of CD4 and CD8 T-cell responses
por: El-Far, Mohamed, et al.
Publicado: (2014)

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor
por: Chabot, Sophie, et al.
Publicado: (2011)

160 Treatment Strategies to Minimize the Impact of Antiretroviral Drug Toxicities
por: Gilliam, Bruce
Publicado: (2014)

Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte‐binding anti‐CD antibody microarray
por: Khvastunova, Alina N., et al.
Publicado: (2018)

Flow Cytometry and Polymerase Chain Reaction-Based Analyses of Minimal Residual Disease in Chronic Lymphocytic Leukemia
por: Uhrmacher, Sabrina, et al.
Publicado: (2010)

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2014)

STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia
por: Liu, Feng-Ting, et al.
Publicado: (2016)

Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2020)

Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia
por: Salama, Mohamed E., et al.
Publicado: (2022)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
por: Ching, Travers, et al.
Publicado: (2020)

Good syndrome presenting with CD8+ T-Cell large granular lymphocyte leukemia
por: Caperton, Caroline, et al.
Publicado: (2015)

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
por: Feller, N, et al.
Publicado: (2013)

Measurable residual disease in the treatment of chronic lymphocytic leukemia
por: Uchiyama, Takayoshi, et al.
Publicado: (2020)

CD160 is essential for NK-mediated IFN-γ production
por: Tu, Tony C., et al.
Publicado: (2015)

CD160 receptor in CLL: Current state and future avenues
por: Oumeslakht, Loubna, et al.
Publicado: (2022)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

BBBBB160 /
por: Kozer, José
Publicado: (2013)

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
por: Rawstron, A C, et al.
Publicado: (2016)

Increased CD160 expression on circulating natural killer cells in atherogenesis
por: Zuo, Jin, et al.
Publicado: (2015)

HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage
por: Muscate, Franziska, et al.
Publicado: (2018)

High Levels of CD244 Rather Than CD160 Associate With CD8(+) T-Cell Aging
por: Wang, Xinyue, et al.
Publicado: (2022)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression
por: Viganò, Selena, et al.
Publicado: (2014)

CD73 Promotes Chronic Lymphocytic Leukemia
por: Allard, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_inmib6mop128mb6ilnqqb5d63r